|
|||||||||
| Level2StockQuotes.com - Level 2 Stock Quotes, Penny Stock Quotes for the Beginner, Novice, Expert or Professional Stock Market Trader.. | |||||||||
|
|||||||||
|
|
Business Summary: KERX
Keryx Biopharmaceuticals, Inc. (Keryx), incorporated in October 1998, is a biopharmaceutical company focused on the acquisition, development, and commercialization of pharmaceutical products for the treatment of life-threatening including renal disease and cancer. The Company is developing Zerenex (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex is in Phase II clinical development for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end stage renal disease (ESRD). Keryx is developing KRX-0401 (perifosine), oral anti-cancer agent that modulates Akt, a protein in the body associated with tumor survival and growth. KRX-0401 is in Phase II clinical development for multiple tumor types. Article: More on KERX KERX reported 1st qtr 2009 earnings of $0.01 per share on 5/13/09. This beat the $-0.08 consensus of the 2 analysts covering the company. Zerenex Zerenex (ferric citrate) is an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex is in Phase II clinical development for the treatment of hyperphosphatemia (elevated serum phosphorous levels) in patients with ESRD in the United States and Japan. In 2008, the Company completed the dosing in the 90-day toxicology study in rats and 16-week toxicology study in canines. These studies will assist the Company in designing the chronic toxicity studies, which the Company is planning, with its Japanese partner. In 2008, Keryx completed its Phase II high-dose tolerance and safety study. KRX-0401 KRX-0401 (perifosine) is an oral anti-cancer agent that modulates Akt, and a number of other key signal transduction pathways, including the JNK and MAPK pathways, all of which are pathways associated with programmed cell death, cell growth, cell differentiation, and cell survival. Over 1,800 patients have been treated with KRX-0401 in trials conducted both in the United States and Europe. Seven Phase I single agent studies of KRX-0401 have been completed; three in Europe by Zentaris and four in the United States by the United States National Cancer Institute (NCI), a department of the National Institutes of Health (NIH), as part of a Co-operative Research and Development Agreement (CRADA). Thirteen Phase 1/2 studies of KRX-0401 in combination with other drugs have been conducted by Keryx. The NCI has completed a number of Phase II clinical trials studying KRX-0401 as a single agent, including studies in prostate, breast, head and neck, and pancreatic cancers, as well as melanoma and sarcomas. In total, nine NCI clinical trials have been conducted across these six tumor types. Keryx Biopharmaceuticals Announces Appointment of Ron Bentsur as Chief Executive Officer NEW YORK, May 20 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (the "Company") (Nasdaq: KERX) announced today the appointment of Ron Bentsur as Chief Executive Officer of the Company. It is also anticipated that Ron Bentsur will join the Company's Board of Directors at the annual meeting of the board on June 16, 2009. Michael P. Tarnok, Interim Chairman of the Company's Board of Directors, stated, "On behalf of the Board, I want to welcome Ron Bentsur to Keryx. Ron is an experienced biopharmaceutical executive who has a proven track-record in creating significant shareholder value. We believe that Ron's leadership abilities and longstanding relationships with the investment, research and banking communities make him ideally-suited to unlock the inherent value of our late-stage pipeline." Mr. Bentsur commented, "I am extremely excited for this opportunity to lead Keryx at this key juncture for the Company. We have two late-stage clinical drug candidates, each with compelling phase 2 data, that we believe have been under appreciated for quite some time. I look forward to introducing our exciting story to the investor community and working to enhance our asset values for the benefit of all of our stakeholders." For more information on Keryx Biopharmaceuticals, Inc. KERX, visit their website at: http://www.keryx.com/ |
|
| Copyright 2010 www.level2stockquotes.com |
| Copyright and Disclaimer - Privacy Policy - Contact-Us - Popular-Links |